Tandem Diabetes Care, Inc.

TNDM Healthcare Medical Devices

Tandem Diabetes Care, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.93% from fiscal 2024. In the quarter to June 2026, revenue grew 5.77%, EPS grew 60.3%, free cash flow fell 146.3% and total debt rose 94.9%, each against the same quarter a year earlier.

16.17 0.35 −2.12%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
−28.1×
Dividend yield
—
F-score
3/9
Altman Z
0.19
Beneish M
−3.10
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(48.03%) (65.73%) (97.88%) (109.73%)

+8 more TTM periods

Piotroski F-Score
4 5 3 3
ROA
(6.24%) (9.11%) (22.15%) (22.20%)
ROIC
(10.33%) (31.96%) (67.83%) (99.30%)
Return on Tangible Assets
(9.95%) (13.09%) (44.60%) (45.98%)
Average Days of Receivables
56.80 49.97 59.53 45.65
Free Cash Flow per Share
(0.39) (0.05) (0.44) (0.37)
Free Cash Flow
(26.62) (3.64) (29.67) (25.12)
Other line items

Show all line items

Columns are period end dates